NASDAQ:TCRR TCR2 Therapeutics (TCRR) Stock Forecast, Price & News $1.48 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.48▼$1.4850-Day Range$1.43▼$1.9852-Week Range$0.82▼$3.88VolumeN/AAverage Volume444,665 shsMarket Capitalization$58.10 millionP/E RatioN/ADividend YieldN/APrice Target$4.91 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability TCR2 Therapeutics MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside232.0% Upside$4.91 Price TargetShort InterestHealthy1.15% of Float Sold ShortDividend StrengthN/ASustainability-0.65Upright™ Environmental ScoreNews Sentiment0.69Based on 4 Articles This WeekInsider TradingAcquiring Shares$577,108 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.68) to ($0.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.28 out of 5 starsMedical Sector5th out of 983 stocksBiological Products, Except Diagnostic Industry2nd out of 164 stocks 4.1 Analyst's Opinion Consensus RatingTCR2 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.91, TCR2 Therapeutics has a forecasted upside of 232.0% from its current price of $1.48.Amount of Analyst CoverageTCR2 Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.15% of the float of TCR2 Therapeutics has been sold short.Short Interest Ratio / Days to CoverTCR2 Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TCR2 Therapeutics has recently decreased by 15.89%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTCR2 Therapeutics does not currently pay a dividend.Dividend GrowthTCR2 Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTCR2 Therapeutics has received a 75.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for TCR2 Therapeutics is -0.65. Previous Next 3.2 News and Social Media Coverage News SentimentTCR2 Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TCR2 Therapeutics this week, compared to 1 article on an average week.Search Interest11 people have searched for TCRR on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TCR2 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TCR2 Therapeutics insiders have bought 337.47% more of their company's stock than they have sold. Specifically, they have bought $577,108.00 in company stock and sold $131,920.00 in company stock.Percentage Held by Insiders25.01% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.76% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TCR2 Therapeutics are expected to grow in the coming year, from ($2.68) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TCR2 Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTCR2 Therapeutics has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About TCR2 Therapeutics (NASDAQ:TCRR) StockTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Read More Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | americanbankingnews.comKevin C. Tang Acquires 50,000 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) StockJune 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 26, 2023 | americanbankingnews.comMpm Asset Management Llc Sells 70,170 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) StockMay 26, 2023 | americanbankingnews.comComparing TCR2 Therapeutics (NASDAQ:TCRR) & Immunocore (NASDAQ:IMCR)May 24, 2023 | americanbankingnews.comTCR2 Therapeutics Inc. (NASDAQ:TCRR) Receives $3.57 Consensus Target Price from BrokeragesMay 16, 2023 | benzinga.comTCR2 Therapeutics Insider Trades Send a SignalMay 12, 2023 | msn.comRecap: TCR2 Therapeutics Q1 EarningsJune 3, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 12, 2023 | americanbankingnews.comKevin C. Tang Purchases 6,774 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) StockMay 12, 2023 | americanbankingnews.comKevin C. Tang Purchases 57,073 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) StockMay 11, 2023 | marketwatch.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | finance.yahoo.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 8, 2023 | americanbankingnews.comInsider Buying: TCR2 Therapeutics Inc. (NASDAQ:TCRR) Major Shareholder Acquires $320,300.16 in StockMay 7, 2023 | americanbankingnews.comKevin C. Tang Buys 18,513 Shares of TCR2 Therapeutics Inc. (NASDAQ:TCRR) StockMay 1, 2023 | americanbankingnews.comBrokerages Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) PT at $3.57April 23, 2023 | americanbankingnews.comTCR2 Therapeutics (NASDAQ:TCRR) and Fate Therapeutics (NASDAQ:FATE) Head-To-Head ComparisonApril 15, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyApril 4, 2023 | americanbankingnews.comBrokerages Set TCR2 Therapeutics Inc. (NASDAQ:TCRR) Target Price at $3.57March 31, 2023 | americanbankingnews.comShort Interest in TCR2 Therapeutics Inc. (NASDAQ:TCRR) Decreases By 19.4%March 26, 2023 | americanbankingnews.comWedbush Reaffirms Neutral Rating for TCR2 Therapeutics (NASDAQ:TCRR)March 26, 2023 | americanbankingnews.comTCR2 Therapeutics' (TCRR) Hold Rating Reiterated at EF Hutton Acquisition Co. IMarch 25, 2023 | msn.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 25, 2023 | americanbankingnews.comTCR2 Therapeutics' (TCRR) Neutral Rating Reiterated at WedbushMarch 24, 2023 | americanbankingnews.comTCR2 Therapeutics (NASDAQ:TCRR) Rating Lowered to Neutral at MizuhoMarch 23, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)See More Headlines TCRR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRR Company Calendar Last Earnings3/23/2023Today6/03/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCRR CUSIPN/A CIK1750019 Webwww.tcr2.com Phone(617) 949-5200FaxN/AEmployees137Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.91 High Stock Price Forecast$13.00 Low Stock Price Forecast$1.68 Forecasted Upside/Downside+232.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.81% Return on Assets-69.35% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.57Miscellaneous Outstanding Shares39,260,000Free Float29,443,000Market Cap$58.10 million OptionableNot Optionable Beta1.95 Key ExecutivesGarry E. MenzelPresident, Chief Executive Officer & DirectorPeter OlagunjuChief Operating OfficerEric M. SullivanChief Financial OfficerAlfonso Quintás-CardamaChief Medical OfficerPraveen MalhotraVice President-Information TechnologyKey CompetitorsTradeUP AcquisitionNASDAQ:UPTDCognition TherapeuticsNASDAQ:CGTXDyadic InternationalNASDAQ:DYAIMiNK TherapeuticsNASDAQ:INKTBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsKevin C TangBought 50,000 shares on 5/25/2023Total: $86,000.00 ($1.72/share)Mpm Asset Management LlcSold 70,170 sharesTotal: $131,919.60 ($1.88/share)Long Focus Capital Management LLCBought 566,270 shares on 5/17/2023Ownership: 1.442%State Street CorpBought 27,900 shares on 5/16/2023Ownership: 0.349%Sagefield Capital LPBought 43,900 shares on 5/15/2023Ownership: 0.112%View All Insider TransactionsView All Institutional Transactions TCRR Stock - Frequently Asked Questions Should I buy or sell TCR2 Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRR, but not buy additional shares or sell existing shares. View TCRR analyst ratings or view top-rated stocks. What is TCR2 Therapeutics' stock price forecast for 2023? 8 analysts have issued twelve-month price targets for TCR2 Therapeutics' stock. Their TCRR share price forecasts range from $1.68 to $13.00. On average, they expect the company's share price to reach $4.91 in the next twelve months. This suggests a possible upside of 232.0% from the stock's current price. View analysts price targets for TCRR or view top-rated stocks among Wall Street analysts. How have TCRR shares performed in 2023? TCR2 Therapeutics' stock was trading at $0.9988 at the start of the year. Since then, TCRR shares have increased by 48.2% and is now trading at $1.48. View the best growth stocks for 2023 here. Are investors shorting TCR2 Therapeutics? TCR2 Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 360,900 shares, a drop of 15.9% from the April 30th total of 429,100 shares. Based on an average daily volume of 602,700 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.2% of the company's shares are sold short. View TCR2 Therapeutics' Short Interest. When is TCR2 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our TCRR earnings forecast. How were TCR2 Therapeutics' earnings last quarter? TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.76. What ETF holds TCR2 Therapeutics' stock ? Harbor Disruptive Innovation ETF holds 18,131 shares of TCRR stock, representing 0.10% of its portfolio. What other stocks do shareholders of TCR2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI). When did TCR2 Therapeutics IPO? (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. What is TCR2 Therapeutics' stock symbol? TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR." Who are TCR2 Therapeutics' major shareholders? TCR2 Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.07%), Long Focus Capital Management LLC (1.44%), Renaissance Technologies LLC (1.13%), Citigroup Inc. (0.98%), Long Focus Capital Management LLC (0.91%) and Dimensional Fund Advisors LP (0.44%). Insiders that own company stock include Alfonso Quintas Cardama, Garry E Menzel, Kevin C Tang, Mayur Ian Somaiya, Mpm Asset Management Llc and Robert Hofmeister. View institutional ownership trends. How do I buy shares of TCR2 Therapeutics? Shares of TCRR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TCR2 Therapeutics' stock price today? One share of TCRR stock can currently be purchased for approximately $1.48. How much money does TCR2 Therapeutics make? TCR2 Therapeutics (NASDAQ:TCRR) has a market capitalization of $58.10 million. The company earns $-151,820,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. How many employees does TCR2 Therapeutics have? The company employs 137 workers across the globe. How can I contact TCR2 Therapeutics? TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The official website for the company is www.tcr2.com. The company can be reached via phone at (617) 949-5200 or via email at investors@tcr2.com. This page (NASDAQ:TCRR) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.